Vaginal Estrogen Tablets Show No Increased Stroke Risk for Postmenopausal Women with Prior Stroke History
A Danish registry study found vaginal estrogen tablets do not increase recurrent stroke risk in postmenopausal women with prior strokes, offering reassurance for safe symptom management in this high-risk population.
A comprehensive analysis of Danish health registry data has revealed that vaginal estrogen tablet use does not increase the risk of recurrent ischemic stroke in postmenopausal women with a history of stroke. Published in Stroke, the journal of the American Heart Association, this research provides crucial safety data for a treatment option that addresses common menopausal symptoms while potentially avoiding the stroke risks associated with systemic hormone therapies.
The study examined prescription records of more than 34,000 postmenopausal women aged 45 and older who had experienced a first ischemic stroke between 2008 and 2017. Researchers compared recurrent stroke rates between women who used vaginal estrogen tablets and those who did not use the treatment. Unlike oral estrogen or transdermal formulations, vaginal tablets dissolve locally and are absorbed through the vaginal mucosa, providing relief for symptoms like vaginal dryness and discomfort during intercourse without significantly elevating systemic estrogen levels.
Lead author Dr. Kimia Ghias Haddadan from Copenhagen University Hospital noted that while systemic hormone replacement therapy is known to increase stroke risk after menopause, there was previously no data on whether vaginal estrogen posed risks for women who had already experienced a stroke. The analysis found no significant association between vaginal estrogen use—whether current, recent, or past use—and increased risk of second stroke. Even high-dose users and those with higher cumulative use showed no elevated risk compared to non-users.
The findings extend previous research from U.S.-based studies like the Women's Health Initiative and Nurses' Health Study, which showed no increased stroke risk with vaginal estrogen in healthy women. This study specifically addresses the safety concerns for a high-risk population often excluded from hormone therapy research. The research methodology utilized Denmark's comprehensive health registries, which accurately track stroke diagnoses, prescriptions, and demographic information across the entire population.
Experts caution that while the results are reassuring, they do not suggest that vaginal estrogen prevents strokes. The study has limitations, including potential health differences between women who used vaginal estrogen and those who didn't, though researchers adjusted for various health and demographic factors. Additionally, prescription records indicate medication was dispensed but not necessarily taken as prescribed. The findings apply specifically to vaginal estrogen tablets, the most common treatment in Denmark, and may not extend to other formulations like creams, patches, or rings.
According to Dr. Haddadan, the results should reassure healthcare professionals caring for postmenopausal women with stroke history, particularly those experiencing troubling menopause symptoms. The study suggests this therapy may safely improve quality of life without increasing stroke risk in this vulnerable population. The research represents an important contribution to understanding treatment options for women navigating both menopausal symptoms and cardiovascular health concerns.